Pro Medicus (ASX: PME) made an announcement this morning about it showcasing its Visage AI Accelerator, which sent the share price higher.
Pro Medicus Limited (ASX:PME) is a Melbourne-based software owner and developer, licensing products to large US hospitals and Australian radiology clinics. The company has offices in Richmond, Victoria, Berlin, Germany and in the United States.
Pro Medicus’ US Announcement
Pro Medicus said that its US subsidiary Visage Imaging Inc will be showcasing the Visage AI Accelerator solution and the new Visage developed breast density classification algorithm at the Radiological Society of North America (RSNA) conference at the start of December 2019.
Visage AI Accelerator is described by Pro Medicus as a multi-faceted, end to end solution translating AI ‘from research to bedside’.
The technology it will be showcasing today includes the Visage 7 AI research server as well as specialised data creation and annotation tools including the new semantic annotation capability to bridge the entire spectrum from research to diagnostic use via a single platform.
A key to this accelerator solution is an open application program interface (API) that enables integration of both Visage and third-party developed algorithms into the Visage 7 product.
Pro Medicus CEO Dr Sam Hupert explained that radiologists don’t want separate systems when it comes to AI, which is why the company developed an open API so that customers could choose the algorithms that best suit their needs whilst being integrated into the Visage 7 Enterprise Imaging Platform.
Dr Hupert said: “We have a pilot implementation of our new Visage 7 semantic annotations ongoing at Partners HealthCare Massachusetts General Hospital (MGH) and Brigham and Women’s Hospital (CWH) Center for Clinical Data Science, where the framework is being defined and tested in the radiology workflow.
“We are also excited to be working closely with the American College of Radiology (ACR) Data Science Institute to integrate Visage 7 and semantic annotations with the ACR AI-LAB, an initiative that offers radiologists tools designed to help them learn the basics of AI and participate directly in the creation, validation and use of health care AI.”
The company will also be highlighting its new breast density classification algorithm (WIP) developed in collaboration with Yale New Haven Health.
Owen's #1 small-cap tech stock of 2020
It's not every day Rask's founder and lead investment analyst shares his exclusive research with the public. However, recently we aired a podcast with Owen's top ASX software stock.
This ASX company is 'hidden' from view because analysts still don't know exactly what it is.
That's why this company is still priced below $250 million. Best of all: Owen thinks it is about to emerge from a 7-year investment drive stronger and more profitable than ever.
Or, you can get Owen's full analysis -- it's also free!
Disclaimer and warning: This information is published by The Rask Group Pty Ltd and contains general financial advice and information. That means, the information/advice does not take into account your objectives, financial situation or needs. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. Please read our Terms of Service and Financial Services Guide before using this website.
At the time of publishing, Jaz does not have a financial interest in any of the companies mentioned.